HMN 214

Drug Profile

HMN 214

Alternative Names: IDEC 160; IVX-214; TV 7101 - Teva; TV-7101

Latest Information Update: 24 May 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nippon Shinyaku
  • Class Antineoplastics; Small molecules; Sulfonamides
  • Mechanism of Action Cyclin-dependent kinase inhibitors; Polo-like kinase 1 inhibitors; Transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 24 May 2010 Discontinued - Phase-I for Solid tumours in Japan (PO)
  • 24 May 2010 Discontinued - Phase-I for Solid tumours in USA (PO)
  • 16 Mar 2007 Teva Pharmaceuticals terminates its licence for HMN 214
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top